Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Express Scripts

Last Updated: August 14, 2022

Details for Patent: 7,273,946

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,273,946 protect, and when does it expire?

Patent 7,273,946 protects VYZULTA and is included in one NDA.

This patent has fifty-three patent family members in thirty-eight countries.

Summary for Patent: 7,273,946
Title:Prostaglandin derivatives
Abstract: Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
Inventor(s): Ongini; Eninnio (Milan, IT), Chiroli; Valerio (Milan, IT), Benedini; Francesca (Milan, IT), Soldato; Piero Del (Milan, IT)
Assignee: Nicox S.A. (Valbonne, FR)
Application Number:11/029,698
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound; Process; Dosage form;

Drugs Protected by US Patent 7,273,946

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bausch And Lomb VYZULTA latanoprostene bunod SOLUTION/DROPS;OPHTHALMIC 207795-001 Nov 2, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,273,946

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 047081 See Plans and Pricing
Argentina 098931 See Plans and Pricing
Australia 2004313688 See Plans and Pricing
Brazil PI0418245 See Plans and Pricing
Canada 2551409 See Plans and Pricing
China 100469765 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.